Literature DB >> 12200756

Autoregulation of endogenous glucose production during hyperglucagonemia.

Ingrid Toft1, John E Gerich, Trond Jenssen.   

Abstract

Increased endogenous glucose production (EGP) contributes to fasting hyperglycemia in type II diabetes. In nondiabetic subjects, increased gluconeogenesis from lactate does not increase EGP. Type 2 diabetes is associated with hyperglucagonemia. The present study was undertaken to examine whether physiologic elevation of plasma glucagon overrides autoregulation of EGP. Eight healthy volunteers were studied on 2 occasions, once during a 3-hour infusion of 30 micromol/kg/min Na-lactate and once during a control infusion of Na-bicarbonate. Plasma glucagon, insulin, and growth hormone were clamped at identical levels in both experiments. Rates of appearance of glucose, lactate, and gluconeogenesis from lactate were measured by tracer techniques. Glucagon infusion rate was elevated when the lactate or bicarbonate infusions were started to induce physiologic hyperglucagonemia. Plasma glucagon increased from baseline levels (234 +/- 21 ng/L and 211 +/- 23 ng/L) to 313 +/- 47 ng/L (bicarbonate experiments) and 329 +/- 43 ng/L (lactate experiments, means +/- SE, P >.3). Lactate infusion increased plasma lactate concentrations from 1.1 +/- 0.9 to 4.6 +/- 0.5 mmol/L (P =.0003). Lactate conversion to glucose increased from 1.5+/-0.3 to 2.8+/-0.8 micromol/kg/min (P =.03) and from 1.7 +/- 0.3 to 8.1 +/- 0.8 micromol/kg/min (P =.0003) in the bicarbonate and lactate experiments, respectively. The increments in lactate conversion to glucose differed significantly (P =.0008). Nevertheless, plasma glucose and EGP were not different in the bicarbonate and lactate experiments: 5.4 +/- 0.5 versus 6.6 +/- 0.7 mmol/L (P =.21), and 10.5 +/- 0.6 versus 11.6 +/- 0.6 micromol/kg/min (P =.19). We conclude that in normal volunteers, neither hyperglucagonemia nor the combination of hyperglucagonemia and increased substrate availability alters the autoregulation of EGP. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200756     DOI: 10.1053/meta.2002.34702

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice.

Authors:  Aidan S Hancock; Aiping Du; Jingxuan Liu; Mayumi Miller; Catherine L May
Journal:  Mol Endocrinol       Date:  2010-06-30

2.  Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice.

Authors:  J Mu; G Jiang; E Brady; Q Dallas-Yang; F Liu; J Woods; E Zycband; M Wright; Z Li; K Lu; L Zhu; X Shen; R Sinharoy; M L Candelore; S A Qureshi; D-M Shen; F Zhang; E R Parmee; B B Zhang
Journal:  Diabetologia       Date:  2011-06-22       Impact factor: 10.122

3.  Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia.

Authors:  S L Conarello; G Jiang; J Mu; Z Li; J Woods; E Zycband; J Ronan; F Liu; R Sinha Roy; L Zhu; M J Charron; B B Zhang
Journal:  Diabetologia       Date:  2006-11-28       Impact factor: 10.122

4.  Islet-1 regulates Arx transcription during pancreatic islet alpha-cell development.

Authors:  Jingxuan Liu; Chad S Hunter; Aiping Du; Benjamin Ediger; Erik Walp; Johanna Murray; Roland Stein; Catherine Lee May
Journal:  J Biol Chem       Date:  2011-03-09       Impact factor: 5.157

5.  Gluconeogenesis and hepatic glycogenolysis during exercise at the lactate threshold.

Authors:  Chi-An W Emhoff; Laurent A Messonnier; Michael A Horning; Jill A Fattor; Thomas J Carlson; George A Brooks
Journal:  J Appl Physiol (1985)       Date:  2012-12-13

6.  Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetes.

Authors:  Md Kamrul Hasan Chowdhury; Nigel Turner; Nicholas L Bentley; Abhirup Das; Lindsay E Wu; Dulama Richani; Sonia Bustamante; Robert B Gilchrist; Margaret J Morris; Peter R Shepherd; Greg C Smith
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

7.  Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist.

Authors:  James Mu; Sajjad A Qureshi; Edward J Brady; Eric S Muise; Mari Rios Candelore; Guoqiang Jiang; Zhihua Li; Margaret S Wu; Xiaodong Yang; Qing Dallas-Yang; Corey Miller; Yusheng Xiong; Ronald B Langdon; Emma R Parmee; Bei B Zhang
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.